- Healthcare consistently ranks as the #1 or #2 issue in most national polls — with cost, coverage, and pre-existing condition protections as the top sub-issues.
- Medicaid expansion has been approved in 40 of 50 states — even in conservative states, Medicaid ballot measures have passed when given a direct vote, bypassing Republican-controlled legislatures.
- The Affordable Care Act's approval rating has reached its all-time high (55%+) — ironically, Republican repeal efforts in 2017 solidified ACA support by making it a real political stakes question.
- Drug pricing is a rare bipartisan issue — 85%+ of Americans support allowing Medicare to negotiate drug prices, making it the most popular healthcare policy proposal regardless of party.
The $800 Billion Medicaid Fight — Now Law
The "One Big Beautiful Bill" reconciliation legislation enacted in 2025 contains approximately $800 billion in Medicaid reductions over 10 years — the largest change to the program in its 60-year history. The Congressional Budget Office projected 10 to 13 million Americans would lose coverage. The law's key mechanisms:
- Work requirements: Able-bodied adults aged 19-64 without dependents would need to document 80 hours per month of work, job training, or community service to maintain eligibility. Research on Arkansas's 2018 pilot found that 18,000 people lost coverage in four months — most of whom were actually working but unable to navigate the reporting requirements.
- Per-capita caps: Federal Medicaid contributions would shift from an open-ended matching model to capped per-enrollee payments, transferring financial risk to states. States facing cost overruns would need to cut benefits, reduce eligibility, or find state revenue — or some combination.
- Enhanced match expiration: The enhanced federal matching funds that incentivized states to expand Medicaid under the ACA would be phased out, making expansion financially less attractive and potentially causing some states to reverse expansion decisions.
- More frequent eligibility redeterminations: States would be required to check eligibility more frequently, a measure that caused 13.7 million people to lose Medicaid coverage during the 2023 "unwinding" after pandemic-era continuous coverage ended — many of whom were later found to have been eligible.
During debate, moderate Republican senators including Susan Collins (ME), Lisa Murkowski (AK), and Josh Hawley (MO) publicly raised concerns about the Medicaid provisions. Their opposition ultimately did not block passage, but their stated reservations now define a potential coalition for any future rollback or relief legislation in 2026.
Healthcare Issue Polling: Party & Demographic Breakdown (2026)
| Issue / Policy | Democrats | Republicans | Independents | National |
|---|---|---|---|---|
| Oppose major Medicaid cuts | 89% | 48% | 68% | 67% |
| ACA favorable view | 82% | 28% | 57% | 56% |
| Medicare drug price negotiation | 94% | 82% | 89% | 88% |
| Support ACA expansion (all states) | 84% | 34% | 61% | 60% |
| Pre-existing condition protections (keep) | 96% | 79% | 88% | 87% |
| Support Medicaid work requirements | 18% | 72% | 44% | 44% |
| Mental health parity enforcement | 91% | 78% | 84% | 84% |
Sources: KFF Health Tracking Poll 2026, Pew Research Center 2025, Gallup 2025. Figures are approximate national averages across multiple polls.
ACA at 56% Approval — Its Most Popular Moment
The Affordable Care Act hit a record 56% net approval rating in 2026 polling — the highest since its 2010 enactment. The trajectory is striking: ACA was deeply underwater in the 2010 midterms that produced a Democratic wave against it. By 2017, as Republicans attempted repeal, ACA favorability surged past 50% for the first time. It has risen steadily since.
The mechanics of the shift: ACA enrollment is real and visible. With 21 million Americans now actively using marketplace plans — many paying subsidized premiums — the program is no longer abstract. When Trump's second-term administration cut outreach funding and tightened special enrollment periods, affected enrollees became an organized constituency. Democratic campaign committees have recruited candidates in competitive districts who are personally enrolled in ACA marketplace plans.
Individual ACA provisions poll even higher than the overall law: pre-existing condition protections at 87% support cut across all party lines. This asymmetry — where "the ACA" remains contested but its specific provisions are loved — has defined the political landscape since 2017. Any candidate who calls for "repealing Obamacare" without instantly specifying what replaces pre-existing condition coverage faces a difficult fight.
GLP-1 Drugs: The New Healthcare Flashpoint
GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, Zepbound — have become one of the fastest-growing drug categories in pharmaceutical history. Originally developed for Type 2 diabetes management, clinical trials showed dramatic weight loss effects: 15-22% body weight reduction, outperforming virtually every previous obesity intervention. The drugs also show cardiovascular benefits independent of weight loss.
The political problem is cost and access. List prices run $900-$1,300 per month. Medicare currently covers GLP-1 drugs only for diabetes patients, not for obesity treatment, due to a 2003 statutory exclusion on weight loss drugs from Medicare Part D. The Biden administration proposed a rule to cover GLP-1s for obesity; the Trump administration reversed it. A 2026 KFF poll found 74% support Medicare coverage — but the 10-year cost estimate runs $145-$300 billion, creating a collision between popular demand and fiscal constraints.
Medicaid coverage varies by state. Several Republican-governed states have restricted GLP-1 Medicaid coverage or imposed strict prior authorization requirements, citing cost. This creates a situation where low-income diabetics in different states access the same drug under different rules — a disparity that Democrats are amplifying as a healthcare equity argument.
Mental Health: The 84% Issue
Mental health parity — the requirement that insurance plans cover mental health and substance use disorder treatment at the same level as physical health — polls at 84% national support with no meaningful partisan gap. The Mental Health Parity and Addiction Equity Act (MHPAEA) has been law since 2008, but enforcement has historically been weak.
The Biden administration issued a major new parity rule in 2024 tightening enforcement and requiring insurers to conduct quantitative comparisons of their mental health coverage limits versus medical/surgical limits. The rule covers approximately 200 million people in employer-sponsored and marketplace plans. The Trump administration delayed implementation pending review. Mental health advocates, veterans' organizations, and bipartisan congressional coalitions have pushed for enforcement, creating an unusual policy window.
For Democrats, mental health parity is strategically valuable: it polls at 84%, affects every demographic, and the specific rollback story — a 2024 rule delayed by the Trump administration — is concrete. For Republicans, opposing parity enforcement is difficult to defend publicly, which is why most Republican resistance operates at the regulatory level rather than through legislation.
Healthcare as the #1 Democratic Attack Line in 2026
13 Million Could Lose Coverage
Democrats are centering their 2026 messaging on the human cost of the CBO's estimate. Medicaid covers 90 million people: nursing home residents, disabled adults, children, pregnant women, and working-poor adults in expansion states. The per-capita cap structure means that even voters who never personally use Medicaid are affected if a family member in a nursing home faces coverage gaps.
Rural Districts Depend on Medicaid
The geographic reality of Medicaid cuts is deeply inconvenient for Republicans. Rural hospitals in Republican-voting districts are disproportionately Medicaid-dependent. West Virginia, Mississippi, Kentucky, Alabama — states that vote Republican by double digits — have Medicaid enrollment rates above 25% of their populations. Hospital associations in these states have publicly opposed the cuts, creating a split between Republican legislators and important local institutions.
IRA Negotiation vs. Rollback
The first Medicare-negotiated drug prices — under the IRA — took effect in 2026, with insulin capped at $35 for Medicare beneficiaries. Democrats will campaign on these tangible savings. Any Republican effort to roll back drug pricing provisions faces 88% public opposition. The asymmetry is notable: the IRA's drug pricing provisions have no organized constituency against them among voters (only among pharmaceutical companies).
Frequently Asked Questions
What do Americans think about Medicaid cuts in 2026?
67% oppose major Medicaid cuts (KFF 2026). Even 48% of Republicans oppose them. The $800B proposed cut covers 10-13 million estimated coverage losses per CBO. Work requirements poll at 44% support when framed as "work requirements for able-bodied adults" — but opposition rises sharply when people learn about the reporting burden and the 2023 Medicaid unwinding, which removed 13.7 million people who were later found eligible.
Is the ACA still popular in 2026?
Yes, at a record 56% approval. Its individual provisions poll even higher: 87% for pre-existing condition protections, 76% for keeping adult children on parental coverage until 26. ACA marketplace enrollment hit 21 million in 2024. The law has never been more popular, which is why no Republican candidate in a competitive district is campaigning on repeal in 2026.
What are GLP-1 drugs and why do they matter politically?
GLP-1s (Ozempic, Wegovy, Mounjaro) are weight-loss and diabetes drugs costing $900-$1,300/month. Medicare currently does not cover them for obesity treatment. 74% of Americans support Medicare coverage for GLP-1 obesity drugs (KFF 2026). The coverage debate intersects with drug pricing, Medicaid spending constraints, and healthcare equity — making it a fast-emerging political issue heading into the 2026 campaign.
How many Americans support expanding Medicare eligibility?
70% of Americans support expanding Medicare to cover more people, including lowering the eligibility age below 65 or creating a public option (KFF 2026). Support includes 51% of Republicans and 76% of voters under 50, making it one of the broadest healthcare majorities in polling. Despite this strong public support, a Medicare expansion is not on the legislative agenda in 2025–2026, as Congress is focused on reconciliation cuts. Democrats are using the 70% figure to highlight the contrast between public preferences and Republican policy direction heading into the 2026 midterms. See the Trump Policy Tracker for the current state of healthcare executive actions.
How does healthcare policy connect to economic concerns for voters?
Healthcare costs are inseparable from economic anxiety: medical debt is the #1 cause of personal bankruptcy in the US, and out-of-pocket costs have risen faster than wages for over a decade. 62% of Americans report skipping or delaying medical care due to cost, and 28% say they have borrowed money or gone into debt to pay medical bills (KFF 2026). The connection is most acute for voters in the 50–65 age bracket who do not yet qualify for Medicare — a demographic concentrated in competitive suburban House and Senate districts. For the broader economic picture, see the Economy & 2026 tracker, and for a look at how immigration intersects with Medicaid funding, see the Immigration issues page.
What Healthcare Polling Means for 2026 Voters
The healthcare debate in 2026 is not abstract. The Republican reconciliation bill's Medicaid provisions are in markup in committees where a handful of moderate Republican senators — including Susan Collins (ME), Lisa Murkowski (AK), and Josh Hawley (MO) — have publicly raised objections. Their votes could determine whether the cuts pass in their current form.
For Senate Democrats in competitive 2026 races, healthcare is the top attack-line issue. In Michigan, Elissa Slotkin is centering Medicaid cuts in her re-election messaging. In Nevada, Jacky Rosen faces a Toss-up race in a state where Medicaid covers more than 800,000 residents. In competitive House districts across the country, the CBO's estimate of 10–13 million coverage losses gives Democratic candidates a concrete number to campaign on.
The 88% bipartisan support for Medicare drug price negotiation is particularly notable: it provides Democrats with a popular defense of the Inflation Reduction Act in virtually every district, including Republican-leaning ones where other aspects of the IRA face opposition.
